A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases.
GX Acquisition Corp has entered into a definitive agreement with Celularity.
News from Celularity:
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Read More Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023…
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
Read More Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 Million October Expected Net Sales of $8.3 Million to $8.9 Million Marks the Highest Single-Month Figure in its History Celularity Filed its Second Quarter Form 10-Q and is Now…
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
Read More FLORHAM PARK, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it has requested a hearing before the Nasdaq Hearings Panel (the “Hearings Panel”) the Nasdaq Listing Qualifications Department’s determination regarding Celularity’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) and…
Celularity Provides Corporate Update
Read More FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage…
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
Read More FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of placental-derived advanced biomaterial products with the acquisition of Rebound, a full thickness placental-derived allograft matrix product, from Sequence LifeScience, Inc. (“Sequence”). “Rebound adds to…
Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
Read More FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder, will present at H.C. Wainwright’s 26th Annual Global Investment Conference being held at the…
Continue Reading Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
[fts_twitter twitter_name=celularity tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]